{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:55:09Z","timestamp":1769694909446,"version":"3.49.0"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Herpes zoster (HZ) is a painful condition caused by reactivation of the varicella-zoster virus. The objectives of this study were to compare HZ incidence in adults with asthma versus adults without asthma and to compare healthcare resource use as well as direct costs in adults with HZ and asthma versus adults with asthma alone in the USA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective longitudinal cohort study included adults aged \u226518 years across the USA. Patients were identified from Optum\u2019s deidentified Clinformatics Data Mart Database, an administrative claims database, between 1 October 2015 and 28 February 2020, including commercially insured and Medicare Advantage with part D beneficiaries. Cohorts of patients with and without asthma, and separate cohorts of patients with asthma and HZ and with asthma but not HZ, were identified using International Classification of Diseases 10th Revision, Clinical Modification codes. HZ incidence, healthcare resource use and costs were compared, adjusting for baseline characteristics, between the relevant cohorts using generalised linear models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HZ incidence was higher in patients with asthma (11.59 per 1000 person-years) than patients without asthma (7.16 per 1000 person-years). The adjusted incidence rate ratio (aIRR) for HZ in patients with asthma, compared with patients without asthma, was 1.34 (95% CI 1.32 to 1.37). Over 12 months of follow-up, patients with asthma and HZ had more inpatient stays (aIRR 1.11; 95% CI 1.02 to 1.21), emergency department visits (aIRR 1.26; 95% CI 1.18 to 1.34) and outpatient visits (aIRR 1.19; 95% CI 1.16 to 1.22), and direct healthcare costs that were US dollars ($) 3058 (95% CI $1671 to $4492) higher than patients with asthma without HZ.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with asthma had a higher incidence of HZ than those without asthma, and among patients with asthma HZ added to their healthcare resource use and costs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2023-002130","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T14:04:08Z","timestamp":1718114648000},"page":"e002130","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-8003","authenticated-orcid":false,"given":"David","family":"Singer","sequence":"first","affiliation":[{"name":"GSK, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Thompson-Leduc","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Ma","sequence":"additional","affiliation":[{"name":"GSK\/Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepshekhar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Menlo Park, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Y","family":"Cheng","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Muthukumar","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Menlo Park, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Devine","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasvi","family":"Sundar","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bogart","sequence":"additional","affiliation":[{"name":"GSK, Research Triangle Park, North Carolina, USA"},{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Hagopian","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Poston","sequence":"additional","affiliation":[{"name":"GSK, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J","family":"Oppenheimer","sequence":"additional","affiliation":[{"name":"Rutgers New Jersey Medical School, Newark, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"2025083112363709000_11.1.e002130.1","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.274"},{"key":"2025083112363709000_11.1.e002130.2","unstructured":"Centers for Disease Control and Prevention . Shingles. Clinical overview. 2020. Available: https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html [Accessed 1 Dec 2022]."},{"key":"2025083112363709000_11.1.e002130.3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40121-021-00581-w","article-title":"A cross-sectional concept elicitation study to understand the impact of herpes zoster on patients' health-related quality of life","volume":"11","author":"Van Oorschot","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2025083112363709000_11.1.e002130.4","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"2025083112363709000_11.1.e002130.5","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"2025083112363709000_11.1.e002130.6","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024. Available: https:\/\/goldcopd.org\/2024-gold-report\/ [Accessed 19 Jan 2024]."},{"key":"2025083112363709000_11.1.e002130.7","first-page":"1","article-title":"Asthma prevalence, health care use, and mortality: United States, 2005-2009","volume":"2011","author":"Akinbami","year":"2011","journal-title":"Natl Health Stat Report"},{"key":"2025083112363709000_11.1.e002130.8","unstructured":"Centers for Disease Control and Prevention . Most recent national asthma data 2020. Available: https:\/\/www.cdc.gov\/asthma\/most_recent_national_asthma_data.htm [Accessed 14 Mar 2023]."},{"key":"2025083112363709000_11.1.e002130.9","unstructured":"Asthma and Allergy Foundation of America . Asthma facts and figures. Available: https:\/\/aafa.org\/asthma\/asthma-facts\/ [Accessed 1 Dec 2022]."},{"key":"2025083112363709000_11.1.e002130.10","first-page":"409","article-title":"Costs of asthma among US working adults","volume":"17","author":"Shenolikar","year":"2011","journal-title":"Am J Manag Care"},{"key":"2025083112363709000_11.1.e002130.11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2015.10.032","article-title":"Asthma as a risk factor for zoster in adults: a population-based case-control study","volume":"137","author":"Kwon","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025083112363709000_11.1.e002130.12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025083112363709000_11.1.e002130.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.009"},{"key":"2025083112363709000_11.1.e002130.14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s41999-018-0096-5","article-title":"Case-control study examining the association between herpes zoster and oral corticosteroids use in older adults","volume":"9","author":"Lai","year":"2018","journal-title":"Eur Geriatr Med"},{"key":"2025083112363709000_11.1.e002130.15","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101137"},{"key":"2025083112363709000_11.1.e002130.16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2019","article-title":"Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study","volume":"54","author":"Lee","year":"2019","journal-title":"Eur Respir J"},{"key":"2025083112363709000_11.1.e002130.17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.anai.2021.01.024","article-title":"Real-world patterns and implications of short-acting Beta(2)-agonist use in patients with asthma in the United States","volume":"126","author":"Lugogo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025083112363709000_11.1.e002130.18","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"2025083112363709000_11.1.e002130.19","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences. 2nd edn. Lawrence Erlbaum Associates, 1988."},{"key":"2025083112363709000_11.1.e002130.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.060"},{"key":"2025083112363709000_11.1.e002130.21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/02770903.2016.1211142","article-title":"Adult asthma is associated with an increased risk of herpes zoster: a population-based cohort study","volume":"54","author":"Peng","year":"2017","journal-title":"J Asthma"},{"key":"2025083112363709000_11.1.e002130.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.04.024"},{"key":"2025083112363709000_11.1.e002130.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200412-1621OC"},{"key":"2025083112363709000_11.1.e002130.24","unstructured":"Food and Drug Administration (FDA) . Shingrix 2023. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix [Accessed 24 Jan 2024]."},{"key":"2025083112363709000_11.1.e002130.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"2025083112363709000_11.1.e002130.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"2025083112363709000_11.1.e002130.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9053"},{"key":"2025083112363709000_11.1.e002130.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30163-X"},{"key":"2025083112363709000_11.1.e002130.29","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2025083112363709000_11.1.e002130.30","unstructured":"Centers for Disease Control and Prevention . Vaccination coverage among adults in the United States, National health interview survey. 2021. Available: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2021.html#print [Accessed 15 Dec 2023]."},{"key":"2025083112363709000_11.1.e002130.31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.japh.2021.11.010","article-title":"Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: a retrospective pharmacy and medical claims analysis","volume":"62","author":"Patterson","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2025083112363709000_11.1.e002130.32","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine"},{"key":"2025083112363709000_11.1.e002130.33","first-page":"502","article-title":"Increased health care resource utilization and costs associated with herpes zoster among patients aged >\/=50 years with chronic obstructive pulmonary disease in the United States","volume":"8","author":"Ghaswalla","year":"2021","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2025083112363709000_11.1.e002130.34","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2337\/dc21-2053","article-title":"Herpes Zoster incidence and burden in adults with type 2 diabetes in the U.S.: a retrospective database analysis","volume":"45","author":"Poirrier","year":"2022","journal-title":"Diabetes Care"},{"key":"2025083112363709000_11.1.e002130.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220986"},{"key":"2025083112363709000_11.1.e002130.36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40744-023-00549-x","article-title":"Clinical and economic burden of herpes zoster in patients with rheumatoid arthritis: a retrospective cohort study using administrative claims","volume":"10","author":"Singer","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025083112363709000_11.1.e002130.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201804-0682CI"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-002130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:36:49Z","timestamp":1756669009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-002130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,11]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjresp-2023-002130"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-002130","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}